Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

September 16th 2024

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

TORL-1-23 Is Tolerable, Active in Heavily Pretreated CLDN6+ Advanced Ovarian Cancer, Other Solid Tumors

September 15th 2024

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

September 15th 2024

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

September 15th 2024

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

September 13th 2024

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Cannavale on the Effect of Comorbidity on Remission Rates in Epithelial Ovarian Cancer

September 11th 2024

Kimberly Cannavale, MPH, discusses the rationale for investigating the effect of pre-existing comorbidities on remission rates in ovarian cancer.

Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic Cancers

September 10th 2024

Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.

FDA Grants Orphan Drug Designation to NXP800 for ARID1a-Deficient Ovarian Cancers

August 29th 2024

NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

Charlson Comorbidities Associated With Lower Likelihood of CR in Epithelial Ovarian Cancer

August 28th 2024

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

CARACO Data Add to Evidence Supporting Omission of Lymphadenectomy in Advanced Ovarian Cancer Without Suspicious Lymph Nodes

August 27th 2024

Jean-Marc Classe, MD, PhD, discusses omitting lymphadenectomy in patients with advanced epithelial ovarian cancer.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26th 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Dr Chambers on the Role of Genetic Testing and PARP Inhibitors in Ovarian Cancer

August 23rd 2024

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Suvemcitug Plus Chemo Boost PFS in Platinum-Resistant Ovarian Cancer

August 4th 2024

Suvemcitug plus chemotherapy improved progression-free survival in platinum-resistant ovarian cancer.

Ceralasertib/Olaparib is Active in Recurrent, Platinum-Sensitive, Recurrent Ovarian Cancer Irrespective of HRD Status

August 3rd 2024

Ceralasertib plus olaparib demonstrated clinical activity in platinum-sensitive, recurrent, high-grade serous ovarian cancer, regardless of HRD status.

IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer

July 30th 2024

IMNN-001 plus perioperative chemotherapy improved overall survival in newly diagnosed, advanced ovarian cancer.

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

July 19th 2024

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Nivolumab/Ipilimumab Yields Responses in Ovarian Clear Cell Carcinoma

July 10th 2024

Don Dizon, MD, discusses updated findings from the BrUOG 354 trial and the future of immunotherapy for patients with ovarian cancers.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

FDA Grants Fast Track Designation to Radspherin for Peritoneal Carcinomatosis From Ovarian Cancer

July 3rd 2024

The FDA has granted fast track designation to Radspherin for the treatment of patients with peritoneal metastases from ovarian cancer.

Dr Mujumdar on Key Trials Evaluating Treatments for Ovarian Cancer

July 2nd 2024

Vaidehi Mujumdar, MD, discusses several key trials that have helped shift the ovarian cancer treatment paradigm.